Maze Therapeutics (NASDAQ:MAZE) Hits New 1-Year High After Analyst Upgrade

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) hit a new 52-week high during trading on Tuesday after Wedbush raised their price target on the stock from $43.00 to $58.00. Wedbush currently has an outperform rating on the stock. Maze Therapeutics traded as high as $53.65 and last traded at $51.26, with a volume of 899720 shares trading hands. The stock had previously closed at $50.21.

A number of other research analysts have also issued reports on MAZE. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Mizuho upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. HC Wainwright reiterated a “buy” rating on shares of Maze Therapeutics in a report on Wednesday, January 28th. Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Finally, Guggenheim lifted their target price on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $58.56.

Insider Buying and Selling

In related news, SVP Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.58, for a total value of $405,800.00. Following the completion of the transaction, the senior vice president directly owned 12,965 shares in the company, valued at approximately $526,119.70. The trade was a 43.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Atul Dandekar sold 72,400 shares of the business’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the sale, the insider directly owned 10,503 shares in the company, valued at $426,001.68. The trade was a 87.33% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 230,000 shares of company stock valued at $9,768,292.

Institutional Trading of Maze Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Maze Therapeutics in the first quarter worth about $57,000. Goldman Sachs Group Inc. bought a new stake in Maze Therapeutics during the 1st quarter worth approximately $145,000. Rhumbline Advisers bought a new stake in Maze Therapeutics during the 1st quarter worth approximately $80,000. Geode Capital Management LLC lifted its stake in Maze Therapeutics by 8.8% in the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock worth $2,838,000 after purchasing an additional 18,773 shares in the last quarter. Finally, Ensign Peak Advisors Inc purchased a new stake in Maze Therapeutics in the 2nd quarter worth approximately $227,000.

Maze Therapeutics Trading Down 1.7%

The company’s fifty day simple moving average is $45.31 and its 200 day simple moving average is $36.41. The stock has a market capitalization of $2.42 billion, a P/E ratio of -2.41 and a beta of 4.47.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.